Drugs and myasthenia gravis: An update

Archives of Internal Medicine

Volumn 157, Issue 4, 1997, Pages 399-408

  Wittbrodt, Eric T ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CONTRAST MEDIUM; CORTICOSTEROID; ERYTHROMYCIN LACTOBIONATE; KANAMYCIN; LEVONORGESTREL; LITHIUM CARBONATE; METHOCARBAMOL; METHYLPREDNISOLONE SODIUM SUCCINATE; NICOTINE; PENICILLAMINE; PHENYTOIN; PRACTOLOL; PREDNISOLONE SODIUM PHOSPHATE; PREDNISONE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; PYRANTEL EMBONATE; QUINIDINE SULFATE; TIMOLOL MALEATE; TRIMETHADIONE; UNINDEXED DRUG; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ASTHMA; BACKACHE; CHILD; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEMALE; GLAUCOMA; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYASTHENIA GRAVIS; MYOPATHY; NEUROMUSCULAR JUNCTION DISORDER; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SMOKING CESSATION; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031040094     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.4.399     Document Type: Review

References (101)

1. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797-1810.
2. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to aeetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054-1059.
3. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. JAMA. 1979;242:623-632.
4. Bucknall RC, Dixon AS, Glick EN, Woodland J, Zutshi DW. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. BMJ. 1975;1:600-602.
5. Czlonkowska A, Myasthenic syndrome during penicillamine treatment. BMJ. 1975;2:726-727.
6. Gordon RA, Burnside JW. D-Penicillamine-induced myasthenia gravis in rheumatoid arthritis. Ann Intern Med. 1977;87:578-579.
7. Masters CL, Dawkins RL, Zilko PJ, Simpson JA, Leedman RJ, Lindstrom J. Penicillamine-associated myasthenia gravis, antiacetylcholine antibodies, and antistriational antibodies. Am J Med. 1977;63:689-694.
8. Russell AS, Lindstrom JM. Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor. Neurology. 1978;28:847-849.
9. Vincent A, Newsom-Davis J, Martin V. Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis. Lancet. 1978;1:1254.
10. Froelich CJ, Hashimoto F, Searles RP, Bankhurst AD. Penicillamine-induced myasthenia gravis in rheumatoid arthritis. J Rheumatol. 1979;6:237-239.
11. Keesey J, Novom S. HLA antigens in penicillamine-induced myasthenia gravis. Neurology. 1979;29:528-529.
12. Sundstrom WR, Schuna AA. Penicillamine-induced myasthenia gravis. Arthritis Rheum. 1979;22:197-198.
13. Albers JW, Hodach RJ, Kimmel DW, Treacy WL. Penicillamine-associated myasthenia gravis. Neurology. 1980;30:1246-1250.
14. Argov Z, Nicholson L, Fawcett PRW, Mastaglia FL, Hall M. Weuromuscular transmission and acetylcholine receptor antibodies in rheumatoid arthritis patients on D-pemcillamine. Lancet. 1980;1:203.
15. Bocanegra T, Espinoza LR, Vasay FB, Germain BF. Myasthenia gravis and penicillamine therapy of rheumatoid arthritis. JAMA. 1980;244:1822-1823.
16. Torres CF, Griggs RC, Baum J, Penn AS. Penicillamine-induced myasthenia gravis in progressive systemic sclerosis. Arthritis Rheum. 1980;23:505-508.
17. Marcus SN, Chadwick D, Walker RJ. D-Penicillamine-induced myasthenia gravis in primary biliary cirrhosis. Gastroenterology. 1984;86:166-168.
18. O'Keefe M, Morley KO, Haining WM, Smith A. Penicillamine-induced ocular myasthenia gravis. Am J Ophthalmol. 1985;99:66-67.
19. Fried MJ, Protheroe T. D-Penicillamine induced myasthenia gravis: its relevance for the anesthetist. Br J Anaesth. 1986;58:1191-1193.
20. Hearn J, Tiliakos NA. Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis. South Med J. 1986;79:1185-1186.
21. Kuncl RW, Pestronk A, Drachman DB, Rechtland E. The pathophysiology of penicillamine-induced myasthenia gravis. Ann Neurol. 1986;20:740-744.
22. Steen VD, Blair S, Medsger TA. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med. 1986;104:699-705.
23. Tzartos SJ, Morel E, Efthimiadis A, et al. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin Exp Immunol. 1988;74:80-86.
24. Katz LJ, Lesser RL, Merikangas JR, Silverman JP. Ocular myasthenia gravis after D-Penicillamine administration. Br J Ophthalmol. 1989;73:1015-1018.
25. Drosos AA, Christou L, Galanopolou V, Tzioufas AG, Tsiakou EK. D-Penicillamine induced myasthenia gravis: clinical, serological and genetic findings. Clin Exp Rheumatol. 1993;11:387-391.
26. Jones E, Sobkowski WW, Murray SJ, Walsh NMG. Concurrent pemphigus and myasthenia gravis as manifestations of penicillamine toxicity. J Am Acad Dermatol. 1993;28:655-656.
27. Raynauld J-P, Lee L, Kornfeld P, Fries JF. Unilateral ptosis as an initial manifestation of D-penicillamine induced myasthenia gravis. J Rheumatol. 1993;20:1592-1593.
28. Adelman HM, Winters PR, Mahan CS, Wallach PM. D-Penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease. Am J Med Sci 1995;309:191-193.
29. 1. J Rheumatol. 1981;8(suppl):169-174.
30. Van Marle W, Woods KL. Acute hydrocortisone myopathy. BMJ. 1980;26:271-272.
31. Williams TJ, O'Hehir R, Czarny D, Horne M, Bowes G. Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. Am Rev Respir Dis. 1988;137:460-463.
32. Janssens S, Decramer M. Corticosteroid-induced myopathy and the respiratory muscles. Chest 1989;95:1160-1162.
33. Miller RG, Milner-Brown HS. Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986;36:729-732.
34. Vallet B, Fourrier F, Hurtevent JF, Parent M, Chopin C. Myasthenia gravis and steroid-induced myopathy of the respiratory muscles. Intensive Care Med. 1992;18:424-426.
35. Panegyres PK, Squier M, Mills KR, Newsom-Davis J. Acute myopathy associated with large parenteral doses of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1993;56:702-704.
36. Norris FH, Colella JAB, McFarlin D. Effect of diphenylhydantoin on neuromuscular synapse. Neurology. 1964;14:869-876.
37. Peterson H. Association of trimethadione therapy and myasthenia gravis. N Engl J Med. 1966;274:506-507.
38. Brumlik J, Jacobs RS. Myasthenia gravis associated with dipnenylhydantoin therapy for epilepsy. Can J Neurol Sci. 1974;1:127-129.
39. So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia. 1981;22:467-473.
40. Booker HE, Chun RWM, Sanguine M. Myasthenia gravis syndrome associated with trimethadione. JAMA. 1970;212:2262-2263.
41. McQuillen MP, Cantor HE, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Arch Neurol. 1968;18:402-415.
42. Moore B, Safani M, Keesey J. Possible exacerbation of myasthenia gravis by ciprofloxacin. Lancet 1988;1:882.
43. Mumford CJ, Ginsberg L. Ciprofloxacin and myasthenia gravis. BMJ. 1990;310:818.
44. Wislicki L, Rosenblum L. Effects of propranolol on the action of neuromuscular blocking drugs. Br J Anaesth. 1967;39:939-942.
45. Werman R, Wislicki L. Propranolol, a curariform and cholinomimetic agent at the frog neuromuscular junction. Comp Gen Pharmacol. 1971;2:69-81.
46. Herishanu Y, Rosenberg P. Beta-blockers and myasthenia gravis. Ann Intern Med. 1975;83:834-835.
47. Hughes RO, Zacharias FJ. Myasthenie syndrome during treatment with practolol. BMJ. 1976;1:460-461.
48. Shaivitz SA. Timolol and myasthenia gravis. JAMA. 1979;242:1611-1612.
49. Verkijk A. Worsening of myasthenia gravis with timolol maleate eyedrops. Ann Neurol. 1985;17:211-212.
50. Coppeto JR. Timolol-associated myasthenia gravis. Am J Ophthalmol. 1984;98:244-245.
51. Neil JF, Himmelhoch JM, Licata SM. Emergence of myasthenia gravis during treatment with lithium carbonate. Arch Gen Psychiatry. 1976;33:1090-1092.
52. Granacher RP. Neuromuscular problems associated with lithium. Am J Psychiatry. 1977;134:702.
53. Lipton ID. Myasthenia gravis unmasked by lithium carbonate. J Clin Psychopharmacol. 1987;7:57.
54. Pestronk A, Drachman DB. Lithium reduces the number of acetylcholine receptors in skeletal muscle. Science. 1980;210:342.
55. Drachman DA, Shom JH. Procainamide: a hazard in myasthenia gravis. Arch Neurol. 1965;13:316-320.
56. Lee DC, Kim YI, Liu HH, Johns TR. Presynaptic and postsynaptic actions of procainamide on neuromuscular transmission. Muscle Nerve. 1983;6:442-447.
57. Niakan E, Bertorini TE, Acchiardo SR, Werner MF. Procainamide-induced myasthenia-like weakness in a patient with peripheral neuropathy. Arch Neurol. 1981;38:378-379.
58. Godley P, Morton TA, Karboski JA, Tami JA. Procainamide-induced myasthenic crisis. Ther Drug Monit. 1990;12:411-414.
59. Miller CD, Oleshansky MA, Gibson KF, Cantilena LR. Procainamide-induced myasthenia-like weakness and dysphagia. Ther Drug Monit. 1993;15:251-254.
60. Ueno S, Takahashi M, Kajiyama K, et al. Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. Neurology. 1987;37:832-833.
61. Liggett SB, Daughaday CC, Senior RM. Ipratropium in patients with COPD receiving cholinesterase inhibitors. Chest. 1988;94:210-212.
62. Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol. 1986;43:255-256.
63. O'Riordan J, Javed M, Doherty C, Hutchinson M. Worsening of myasthenia gravis on treatment with imipenem/cilastatin. J Neurol Neurosurg Psychiatry. 1994;57:383.
64. Absher JR, Bale JF. Aggravation of myasthenia gravis by erythromycin. J Pediatr. 1991;119:155-156.
65. May EF, Calvert PC. Aggravation of myasthenia gravis by erythromycin. Ann Neurol. 1990;28:577-579.
66. Bescansa E, Nicolas M, Aguado C, Toledano MA, Vinals M. Myasthenia gravis aggravated by pyrantel pamoate. J Neurol Neurosurg Psychiatry. 1991;54:563.
67. Lecky B, Weir D, Chong E. Exacerbation of myasthenia gravis by propafenone. J Neurol Neurosurg Psychiatry. 1991;54:377.
68. Swash M, Ingram DA. Adverse effect of verapamil in myasthenia gravis. Muscle Nerve. 1992;15:396-398.
69. Reverte M. Adverse effect of verapamil in myasthenia gravis: an additional comment. Muscle Nerve. 1993;18:879-880.
70. Sghirlanzoni A, Mantegazza R, Mora M, Pareyson D, Cornelio F. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve. 1988;11:114-119.
71. Robberecht W, Bednarik J, Bourgeois P, van Hees J, Carton H. Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. Arch Neurol. 1989;46:464-468.
72. Baraka A, Taha S, Yazbeck V, Rizkallah P. Vecuronium block in the myasthenic patient. Anaesthesia. 1993;48:588-590.
73. Eisenkraft JB, Book WJ, Mann SM, Papatestas AE, Hubbard M. Resistance to succinylcholine in myasthenia gravis: a dose-response study. Anesthesiology. 1988;69:760-763.
74. 2 anaesthesia in a patient with active myasthenia gravis receiving long-term anticholinesterase therapy. Anaesthesia. 1994;49:509-511.
75. Baraka A, Wakid N, Mansour R, Haddad W. Effect of neostigmine and pyridostigmine on plasma cholinesterase activity. Br J Anaesth. 1981;53:849-851.
76. Baraka A. Suxamethonium block in the myasthenic patient: correlation with plasma cholinesterase. Anaesthesia. 1992;47:217-219.
77. Seigne RD, Scott RPF. Mivacurium chloride and myasthenia gravis. Br J Anaesth. 1994;72:468-469.
78. Ramsey FM, Smith GD. Clinical use of atracuhum in myasthenia gravis: a case report. Can Anaesth Soc J. 1985;32:642-645.
79. O'Flaherty D, Pennant JH, Rao K, Giesecke AH. Total intravenous anesthesia with propofol for transdermal thymectomy in myasthenia gravis. J Clin Anesth. 1992;4:241-244.
80. Meyer D, Hamilton RC, Gimbelt HV. Myasthenia gravis-like syndrome induced by topical ophthalmic preparations. J Neuroophthalmol. 1992;12:210-212.
81. Carmignani M, Scoppetta C, Ranalletti FO, Tonali P. Adverse interaction between acetazolamide and anticholinesterase drugs at the normal and myasthenic neuromuscular junction level. Int J Clin Pharmacol Ther. 1984;22:140-144.
82. Maebashi M, Kawanura N, Sat M, Imamura A, Yoshinaga K. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinemia. Lancet. 1978;2:805.
83. Guarnieri GF, Ranieri F, Toigo G, et al. Lipid lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr. 1980;33:1489-1492.
84. Bazzato G, Mezzina C, Ciman M, Guarneri G. Myasthenia-like syndrome associated with carnitine in patients on long-term haemodialysis. Lancet. 1979;1:1041-1042.
85. Bazzato G, Coli U, Landini S, Mezzina C, Ciman M. Myasthenia-like syndrome after D,L- but not L-carnitine. Lancet. 1981;1:1209.
86. Perez A, Perella M, Pastor E, Cano M, Escudero J. Myasthenia gravis induced by alpha-interferon therapy. Am J Hematol. 1995;49:365-366.
87. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P. Myasthenia gravis during interferon alfa therapy. Neurology. 1995;45:382-383.
88. Brittain J, Lange LS. Myasthenia gravis and levonorgestrel implant. Lancet. 1995;2:1556.
89. Podrizki A. Methocarbamol and myasthenia gravis. JAMA. 1968;205:938.
90. Moreau T, Depierre P, Brudon F, Confavreux C. Nicotine-sensitive myasthenia gravis. Lancet. 1994;1:548-549.
91. Pethica D. Nicotine-sensitive myasthenia gravis. Lancet 1994;1:961.
92. Moreau T, Vandenabeele S, Depierre P, Confavreux C. Nicotine-sensitive myasthenia gravis. Lancet 1995;1:61-62.
93. Canal N, Franceschi M. Myasthenic crisis precipitated by iothalamic acid. Lancet. 1983;1:1288.
94. Chagnac Y, Hadani M, Goldhammer Y. Myasthenic crisis after intravenous administration of iodinated contrast agent. Neurology. 1985;35:1219-1220.
95. Eliashiv S, Wirgiun I, Brenner T, Argov Z. Aggravation of human and experimental myasthenia gravis by contrast media. Neurology. 1990;40:1623-1625.
96. Rocha M de S, Bacheschi LA. Exacerbation of myasthenia gravis by contrast media. AJR Am J Roentgenol. 1994;162:997.
97. Frank JH, Cooper GW, Black WC, Phillips LH. Iodinated contrast agents in myasthenia gravis. Neurology. 1987;37:1400-1402.
98. Foulks CJ. Myasthenia gravis presenting as laryngeal stridor after exposure to chlorine gas. South Med J. 1981;74:1423-1424.
99. Kailin EW, Hastings A. Electromyographic evidence of DDT-induced myasthenia. Med Ann DC. 1966;35:237-244.
100. Kornfeld P, Horowitz SH, Genkins G, Papatestas AE. Myasthenia gravis unmasked by antiarrhythmic agents. Mt Sinai J Med. 1976;43:10-14.
101. Confavreux C, Charles N, Aimard G. Fulminant myasthenia gravis soon after initiation of acebutolol therapy. Eur Neurol. 1990;30:279-281.